These links are provided for information only. NPPG is not responsible for the content of any link
December 2019
- Approval of licence extension for cystic fibrosis therapy ivacaftor (Kalydeco)
- Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
- Association Between Fertility Treatment and Cancer Risk in Children
- Summary of American Academy of Neurology guideline for acute treatment of migraine in children and adolescents and pharmacologic treatment for paediatric migraine prevention
- Does general anaesthesia affect neurodevelopment in infants and children?
- Revised SPC: Diovan 3 mg/ml Oral Solution (valsartan) – licensed for ages 1 to 6
- Clinical Commissioning Policy: Maternal intravenous immunoglobulin (IVIg) for the prevention of allo-immune fetal and neonatal haemochromatosis
- HPV: WHO calls for countries to suspend vaccination of boys
- National measles guidelines
November 2019
- General Pharmaceutical Council launches new guidance for pharmacist prescribers to ensure safe and effective prescribing
- Supply Disruption Alert: Emerade 150 microgram, 300 microgram and 500 microgram adrenaline auto-injector devices
- FDA approves Toujeo (insulin glargine) to treat childhood type 1 diabetes
- Educational Risk Minimisation Materials to help reduce the risk associated with using glycopyrronium bromide (Sialanar) 320 micrograms /ml Oral Solution
- November BNF/BNFC Newsletter
- Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infection: a prospective cohort study
- Pre-school vaccinations: guide to vaccinations from 2 to 5 years
- Revised SPC: Qvar (beclometasone dipropionate) MDI – all strengths – pescribing information for 5 years and above
- Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study
- Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations
- School-based interventions to prevent anxiety and depression in children and young people: a systematic review and network meta-analysis
- Practical aspects of childhood epilepsy
- Flu-vaccine nasal spray delayed for some schoolchildren
- Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome – Final Appraisal Determination
- Urgent Policy Statement: Cystic Fibrosis Modulator Therapies
- Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
- Sanofi presents data from EDITION JUNIOR phase III trial of Toujeo (insulin glargine 300 Units/mL) vs. insulin glargine 100 Units/mL (Gla-100) in children and adolescents aged 6 to 17 years with type 1 diabetes
- NIHR Signals: Antimicrobial central venous catheters do not reduce infections in pre-term babies
- Fever in under 5s: assessment and initial management- guidance (NG143)
- Paediatric critical care and surgery in children review: Summary report
- Human and animal bites: antimicrobial prescribing – Draft guidance consultation
- Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial
- Immunisations: babies up to 13 months of age
- FDA statement on new testing results, including low levels of impurities in ranitidine drugs
- Narsoplimab receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan required for licensing application
- Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood
- Zanamivir (Dectova®)
- Belimumab licence extension for use in children from age 5 approved in the European Union
- BNF/BNFC newsletter October 2019
October 2019
- Investigation into pre-school vaccinations routinely provided in England in 2018/2019
- FDA approves license extension for Botulinum A toxin for treatment of lower limb spasticity in children and adolescents aged 2 to 17 years
- Perinatal Management of Extreme Preterm Birth before 27 weeks of gestation: A Framework for Practice
- Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial
- Incidence of anorexia nervosa in young people in the UK and Ireland: a national surveillance study
- Committee for Medicinal Products for Human Use (CHMP) recommends approval of Baqsimi (glucagon)
- Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort
- Letter to healthcare professionals regarding parenteral nutrition products for neonates and children below 2 years of age – protect from light
- Adrenaline auto-injectors: recent actions taken to support safety
- Differences in lung function between children with sickle cell anaemia from West Africa and Europe
- Duration of intravenous antibiotic therapy in people with cystic fibrosis
- NICE draft Quality Standard published for consultation: Specialist neonatal respiratory care for babies born preterm
- Band ligation versus beta‐blockers for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
- Mandatory childhood vaccination could cause “irreparable damage,” says expert panel
- Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis
- Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
- Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis
- Gastro-oesophageal reflux disease in children and young people: diagnosis and management – updated guidance (NG1)
- Fetal Alcohol Spectrum Disorder (FASD)
- New product: Epidyolex (cannabidiol) 100 mg/ml oral solution
- FDA accepts for review two New Drug Applications (NDAs) for fidaxomicin to treat children aged six months up to 18 years with Clostridium difficile infections
- Epilepsies: diagnosis and management- updated clinical guideline (CG137)
September 2019
- September 2019 BNF/BNFc newsletter
- US FDA approves Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids
- Pfizer announces positive results for abrocitinib in atopic dermatitis for patients 12 and older
- Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions
- Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
- Ipsen announces FDA approval of Dysport (abobotulinumtoxinA) for treatment of upper limb spasticity in children, excluding cerebral palsy
- DTB Commentary: Do oral steroids improve hearing outcomes in children with otitis media with effusion?
- TNF‐α blockers for the treatment of Kawasaki disease in children
- Childhood Vaccination Coverage Statistics – England 2018-19
- Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
- Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
- European CHMP issues positive opinion for paediatric license extension of belimumab (Benlysta)
- Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis
- Pneumonia (hospital-acquired): antimicrobial prescribing- guideline [NG139]
- Sulthiame add‐on therapy for epilepsy
- Attention deficit hyperactivity disorder: diagnosis and management – updated guidance (NG87)
- UK immunisation schedule: the green book, chapter 11 updated
- FDA approves hydroxyprogesterone caproate (HPC) to prevent preterm birth
- Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
- Methylphenidate and stuttering
- Neonatal parenteral nutrition – draft guidance
- Temporal Trends and Contemporary Use of Insulin Pump Therapy and Glucose Monitoring Among Children, Adolescents, and Adults With Type 1 Diabetes Between 1995 and 2017
- Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study
- Twin and triplet pregnancy – guidance (NG137)
- NHS warning to parents as ‘asthma season’ hits
- August BNF/BNFC eNewsletter
- Vancomycin is commonly under‐dosed in critically ill children and neonates
- Revised SPCs: Strensiq (asfotase alfa) solution for injection (all strengths)
August 2019
- WHO revision of pain management guidelines
- Four European nations lose measles eradication status
- HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study
- MMR vaccine for 10 to 11 year old children: information for GPs
- Cannabidiol for adjuvant treatment of seizures associated with Dravet syndrome – Appraisal Consultation document
- Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome – appraisal consultation document
- European Commission grants extension of indication for Fiasp (insulin aspart) for use in children
- Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)
- Estimated 1 in 7 five years olds are not immunised against MMR
- NHS England to look at offering childhood vaccinations in healthcare settings other than general practice to increase childhood vaccine coverage
- Revised SPC: Dupixent (dupilumab) 300 mg solution for injection in pre-filled syringe – new paediatric indication
- Efficacy of oral amoxicillin–clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial
- Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis
- Association of Gluten Intake During the First 5 Years of Life With Incidence of Celiac Disease Autoimmunity and Celiac Disease Among Children at Increased Risk
- Antibiotic exposure and ‘response failure’ for subsequent respiratory tract infections: an observational cohort study of UK preschool children in primary care
- Inhaled corticosteroids for cystic fibrosis
- Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children
- New products: Amglidia (glibenclamide) 0.6 mg/mL and 6 mg/mL, oral suspension
- How and why porcine gelatine is used in vaccines for immunisation programmes
- A quick reference guide to Flu vaccines for children for winter 2019 to 2020
- Long-term risk of infections after treatment of childhood leukemia: a population-based cohort study using administrative health data
- Interventions for preventing obesity in children
- What were the impacts of the Committee on Safety of Medicines warning and publication of the NICE guidelines on trends in child and adolescent antidepressant prescribing in primary care? A population based study
- Manufacturers report positive results for dupilumab for severe atopic dermatitis in children aged 6-11 years
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
- Respiratory syncytial virus (RSV): a scourge from infancy to old age
- Unmasking the vulnerabilities of uninfected children exposed to HIV
- Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth
- Probiotics for preventing acute otitis media in children
- Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I
- Educational Risk Minimisation Materials to help reduce the risk associated with the use of glycopyrronium bromide 1 mg/5 ml oral solution
- Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants
- Preterm labour and birth – updated guideline (NG25)
- Lipid emulsions for parenterally fed term and late preterm infants
- Lipid emulsions for parenterally fed preterm infants
July 2019
- European CHMP issues positive opinion recommending approval of license extension for Lucentis (ranibizumab) for treatment of ROP in preterm infants
- British guideline on the management of asthma- update
- Nusinersen for treating spinal muscular atrophy-technology appraisal guidance (TA588)
- Young people among those set to benefit from “hole in the heart” closure as part of the NHS Long Term Plan
- Variabilities in Childhood Cardiovascular Risk Factors and Incident Diabetes in Adulthood: The Bogalusa Heart Study
- Associations of Blood Pressure and Cholesterol Levels During Young Adulthood With Later Cardiovascular Events
- NIHR Signal: Levetiracetam is a useful alternative to phenytoin in stopping prolonged epileptic seizures in children
- NIHR Signal Insights into the transfer between children’s and adults’ services for young people with selected long-term conditions
- Autumn 2019: Complete Routine Immunisation Schedule
- Revised SPCs: Numeta E emulsion for infusion (all strengths).
- Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study
- From September 2019, boys in school year 8 to be offered the free Human Papilloma Virus (HPV) vaccine
- Conference report: positive results reported for rivaroxaban in paediatric venous thromboembolism
- Vitamin D for secondary prevention of acute wheeze attacks in preschool and school-age children
- Nusinersen (Spinraza) access agreement extended for paediatric spinal muscular atrophy
- Behind the Headlines: Asthma attacks triple when children return to school in September
- Suspected neurological conditions: recognition and referral – guidance (NG127)
- Intravenous sildenafil fails to provide benefit for treatment of neonates with persistent pulmonary hypertension (PPHN)
- Pediatric Post–Cardiac Arrest Care: A Scientific Statement From the American Heart Association
- Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association
- Phase 4 CrisADe CARE 1 study evaluating crisaborole ointment 2% in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis meets primary safety endpoints
- Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: The AML08 Multicenter, Randomized Phase III Trial
- Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer
- Enteral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates
June 2019
- Tackling childhood obesity: £1.5 million funding for local projects
- Depression in children and young people: identification and management – guidance (NG134)
- Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial
- NIHR Signal: antimicrobial central venous catheters (CVCs) do not reduce infections in pre-term babies
- Pneumococcal conjugate vaccines for preventing acute otitis media in children
- Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes
- US FDA approves liraglutide (Victoza) for type 2 diabetes in children aged over 10 years
- The evolving research agenda for paediatric tuberculosis (TB) infection
- NHS England seeks feedback from commissioners on childhood obesity strategy
- Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study
- Updated guidelines on post-exposure prophylaxis for measles issued
- US FDA grants priority review to rituximab in combination with glucocorticoids for treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children from age two years
- The association between maternal body mass index and child obesity: A systematic review and meta-analysis
- Adjusting the dose in paediatric care: dispersing four different aspirin tablets and taking a proportion
- fluticasone propionate/formoterol fumarate (Flutiform®) accepted for use within NHSScotland in children aged 5-12 years
- fingolimod (Gilenya®) accepted for use within NHSScotland in children aged 10-18 years
- Increasing influenza immunisation uptake among children – leaflet for general practice
- Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial
- Childhood Asthma Management in Primary Care – Implementation of Exhaled Nitric Oxide and Spirometry Testing (CHAMPIONS study)
- Should measles vaccination be compulsory?
- Pivotal phase III ARTEMIS trial reports consistent safety and efficacy of AR101 in children and adolescents with peanut allergy
- Rotavirus vaccine (Rotarix®): patient group direction (PGD) template (updated)
- MenACWY vaccine (Menveo® or Nimenrix®): patient group direction (PGD) template (updated)
- Transition between child and adult services for young people with attention-deficit hyperactivity disorder (ADHD): findings from a British national surveillance study
- Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder
- Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events
- Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT
May 2019
- May BNF/BNFC eNewsletter
- Prevalence of maternal mental illness among children and adolescents in the UK between 2005 and 2017: a national retrospective cohort analysis
- US FDA approves gene therapy onasemnogene abeparvovec-xioi to treat paediatric patients (less than 2 years of age) with spinal muscular atrophy (SMA)
- Maternal and fetal outcomes in pregnancies complicated by Marfan syndrome
- Interventions to improve the mental health of children and young people with long-term physical conditions: linked evidence syntheses
- Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder—outcome measures beyond symptom control and clinical trials
- Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study
- Association of Changes in Air Quality With Incident Asthma in Children in California, 1993-2014
- Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery
- Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps
- US FDA approves nasal midazolam for acute repetitive seizures
- Fragmin (dalteparin sodium) approved by FDA as first anticoagulant for children
- Hepatic late adverse effects after antineoplastic treatment for childhood cancer
- Long‐term antibiotics for preventing recurrent urinary tract infection in children
- Probiotics for the prevention of paediatric antibiotic‐associated diarrhoea
- The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study
- Association of Gestational Weight Gain With Adverse Maternal and Infant Outcomes
- New Product: Sprycel (dasatinib) 10 mg/mL powder for oral suspension
- Epanutin (phenytoin) 50mg Infatabs (Pfizer) supply issue
- Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study
- US FDA approves amifampridine for children with Lambert-Eaton myasthenic syndrome
- Health Secretary considers ‘all options’ to boost vaccine uptake
- Revised SPC: Bramitob (tobramycin) Nebuliser Solution
- New Product: Sprycel (dasatinib) 10 mg/mL powder for oral suspension
- Interventions for infantile seborrhoeic dermatitis (including cradle cap)
- Conference abstract – RCT reports cannabidiol (CBD) reduces convulsive seizure frequency in children and adolescents with Dravet syndrome
April 2019
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis
- Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety
- Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer
- Liraglutide in Children and Adolescents with Type 2 Diabetes
- UNICEF reports over 20 million children worldwide missed out on measles vaccine annually in past 8 years creating a pathway to current global outbreaks
- BioMarin confirms all UK patients who took part in clinical trials of sapropterin dihydrochloride (Kuvan) for phenylketonuria (PKU) will be able to access drug after trials end
- Association of Exposure to Infections in Childhood With Risk of Eating Disorders in Adolescent Girls
- Revised SPCs: ORENCIA (abatacept) 50, 87.5 and 125mg solution for injection (pre-filled syringe)
- Revised SPC: Epistatus 10 mg Oromucosal Solution – Carer instructions for administration updated
- Brivaracetam add‐on therapy for drug‐resistant epilepsy
- Innovative child malaria vaccine to be tested in Malawi
- Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study
- Hepatitis C virus infection in children and adolescents
- Hepatitis B virus infection in children and adolescents
- UK immunisation schedule: the green book, chapter 11 (updated)
- Probiotics to prevent infantile colic
- Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme
- Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial
- Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial
- Rapid Over Infusion of Parenteral Nutrition (PN)- update to Patient Safety Alert NHS/PSA/W/2017/005 issued Sept 2017
- NHS staff and parents to gain access to crucial child health information
- Hepatitis virus infection in children and adolescents
- Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study
- Saving Babies’ Lives Version Two: A care bundle for reducing perinatal mortality
- Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT
- Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial
- Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial
- Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study
- Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation
- NIHR Signal: Does an antibacterial milk protein reduce infection in premature babies?
- Specialist neonatal respiratory care for babies born preterm (NG 124) – guidance
- New presentation: Fycompa (perampanel) 0.5 mg/ml oral suspension
- February BNF/BNFC eNewsletter
March 2019
- Transforming children’s services
- Association of Prenatal Cannabis Exposure With Psychosis Proneness Among Children in the Adolescent Brain Cognitive Development (ABCD) Study
- Antibiotic treatment for newborns with congenital syphilis
- Current and Future Challenges for Children Across the World
- NHS England Specialised Commissioning document: Selective Dorsal Rhizotomy for treatment of spasticity in cerebral palsy
- Chloramphenicol: is it safe in breastfeeding?
- Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
- High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years
- NHS and Vertex remain deadlocked over price of Orkambi (lumacaftor/ivacaftor)
- Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA)
- Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial
- Association of Atopic Dermatitis With Sleep Quality in Children
- First 1000 days of life
- A priori choice of neuraxial labour analgesia and breastfeeding initiation success: a community-based cohort study in an Italian baby-friendly hospital
- What is the sodium content of medicines?
- First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
- Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial
- Postoperative epidural analgesia versus systemic analgesia for thoraco‐lumbar spine surgery in children
- Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study
- Theophylline and aminophylline for prevention of acute kidney injury in neonates and children: a systematic review
- Biologics for paediatric severe asthma: trick or TREAT?
- School‐based self‐management interventions for asthma in children and adolescents: a mixed methods systematic review
February 2019
- Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association
- Pertussis (whooping cough)
- Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial
- Universal antenatal screening for group B streptococcus may cause more harm than good
- Topiramate for juvenile myoclonic epilepsy
- Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): an international, multicentre, randomised, controlled equivalence trial
- Spina bifida: information for parents
- Althea to launch cannabis based products in the UK
- Eisai submits application to extend licence of perampanel to include treatment of paediatric patients with epilepsy
- Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort
- Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis
- Child abuse and neglect- quality standard (QS179)
- Cases of measles in Europe at highest rate in a decade due to growing number of areas where parents are refusing vaccination for their children
- European Commission approves dasatinib in combination with chemotherapy for treatment of paediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia
- Adoption of Peristeen at Alder Hey Children’s Hospital
- New product: OZALIN (midazolam) 2 mg/ml oral solution in single-dose container
- Education Secretary announces that up to 370 schools in England will take part in a series of trials testing different approaches to supporting young people’s mental health
- January 2019 BNF/ BNF C eNewsletter
- Childhood obesity: time for action report – government response
- European CHMP recommends license extension of abatacept (Orencia) for treatment of olyarticular juvenile idiopathic arthritis
- European CHMP recommends atazanavir (Atazanavir Krka) for treatment of HIV-1 in adults and children 6 years of age and older
- Mental health trial launches in schools in England
January 2019
- Limited evidence for non-drug treatment of childhood ADHD: DTB Select summary
- Seizures and quinolone antibiotics in children: a systematic review of adverse events
- Early access to medicines scheme (EAMS) scientific opinion: Dupilumab as a treatment of adolescent patients between 12 and 18 years of age with severe atopic dermatitis for whom the available systemic therapies are not suitable
- Depression in children and young people: identification and management – DRAFT guidance
- Children and young people exposed prenatally to alcohol
- Determining the reasons for poorly controlled asthma in an adolescent
- European Commission approves paediatric license extension of Orkambi (lumacaftor/ivacaftor) for cystic fibrosis
- Mental health services for children and young people
- PCV (13-valent, adsorbed): patient group direction (PGD) template
- Flutiform (fluticasone/ formoterol) approved in EU for treatment of children with asthma aged five years and over
- Tiotropium (Spiriva® Respimat®) for asthma in paediatric patients
- Sedation of children undergoing dental treatment
- Recombinant growth hormone therapy for cystic fibrosis in children and young adults
- Maternal probiotic supplementation for prevention of morbidity and mortality in preterm infants
- Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial
- Childhood cancer burden: a review of global estimates
- Revised SPC: Ravicti (glycerol phenylbutyrate) 1.1 g/ml oral liquid
- Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above): Clinical Commissioning Policy
For older news click here